细分品类中，港股市场ETF净流出额居前，净流出17.7亿元。规模变化方面，宽基ETF规模下降205.15 亿元。具体到指数维度，5月23日，跟踪中证A500指数的ETF单日净流出额居前，达11.13亿元。 从单只基金看，创新药ETF单日净流出额居前，达5.87亿元。此外，上证50ETF、中证A500ETF龙头等 核心宽基指数ETF、以及港股通互联网ETF、港股创新药均遭资金净流出。 业内表示，尽管，4月受关税政策以及全球经济形势数据等因素，港股行情波动剧烈，但是，5月以来， 行情回暖显著，因此一些资金开始对港股相关指数"获利了结"。受益于政策支持与技术突破，近期A 股、港股创新药板块双双表现强势，也有一些资金选择"落袋为安"。 据中信建投证券统计，2024年医保谈判中创新药成功率超90%，国产占比达70%以上，商保政策密集出 台，为创新药支付端提供增量可能。资金面上，今年以来，创新药板块持续获得增量资金流入，上周有 较大幅度净流出，流出程度在所有指数中排名第四。 【导读】上个交易日股票ETF市场资金净流出27亿元 中国基金报记者张燕北 上周五（5月23日），A股三大股指收跌。当日，股票ETF（含跨境ETF，下 ...

Industry Investment Rating - The industry investment rating is "Outperform" [2] Core Viewpoints - The report highlights that the recent licensing deal between 3SBio and Pfizer for the PD-1/VEGF bispecific antibody SSGJ-707 marks a record in overseas transactions for Chinese innovative pharmaceutical companies, indicating a potential surge in licensing out activities [5][13] - The global market for bispecific antibodies is projected to exceed $80 billion by 2030, with PD-1/VEGF bispecifics being a focal point for multinational pharmaceutical companies [20] - In 2024, the total licensing out amount for Chinese innovative drugs surpassed $51.9 billion, a year-on-year increase of 27.4%, accounting for 30% of the global total [23] Summary by Sections Weekly Insights - 3SBio's licensing agreement with Pfizer involves an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion, along with a tiered sales revenue share [13][14] - The report notes that the biopharmaceutical sector has seen a weekly increase of 1.78%, outperforming the CSI 300 index by 1.96 percentage points [24][29] Subsector Performance - The report details that the biopharmaceutical sector's performance is diverse, with the other bioproducts sector showing the highest increase of 4.09%, while the hospital sector experienced the largest decline of 1.07% [6][28] Recommended and Benefiting Stocks - Recommended stocks include Weikang Medical, Maipu Medical, and Yifeng Pharmacy, among others [7][40] - Benefiting stocks from the recent trends include Hualan Biological Engineering, BGI Genomics, and Mindray Medical [7][45] Market Trends - The report emphasizes the acceleration of licensing out activities for Chinese pharmaceutical companies, with a notable increase in both the number and value of transactions in recent years [23][25] - The report suggests that the medical device sector is expected to see significant growth due to policy changes and increased procurement activities [31]

Investment Rating - The industry investment rating is "Outperform" [2] Core Insights - The report highlights that the recent licensing deal between 3SBio and Pfizer for the PD-1/VEGF bispecific antibody SSGJ-707 marks a record in overseas transactions for Chinese innovative pharmaceutical companies, indicating a potential surge in licensing out activities [5][13] - The global market for bispecific antibodies is projected to exceed $80 billion by 2030, with PD-1/VEGF bispecifics being a focal point for multinational pharmaceutical companies [5][20] - In 2024, the total amount of licensing out agreements for Chinese innovative drugs surpassed $51.9 billion, a year-on-year increase of 27.4%, accounting for 30% of the global total [5][23] Industry Performance - The pharmaceutical sector saw an increase of 1.78% this week, outperforming the CSI 300 index by 1.96 percentage points, ranking first among 31 sub-industries [24][29] - The biopharmaceutical sector experienced the highest growth this week, with a rise of 4.09% [6][28] Subsector Highlights - The report identifies several subsectors with notable performance: - Other biopharmaceuticals increased by 4.09% - Raw materials and medical research outsourcing sectors also saw increases of 4.03% and 3.6% respectively [6][28] - The report recommends several stocks, including Weikang Medical, Maipu Medical, and Yifeng Pharmacy, as potential beneficiaries of the current market dynamics [7][40] Clinical Development - SSGJ-707 has shown promising clinical data, with an overall response rate (ORR) of 70.8% in PD-1 positive NSCLC patients and a disease control rate (DCR) of 100% [17][20] - The drug is currently in Phase III clinical trials and has received breakthrough therapy designation in China [16][20] Market Trends - The report notes a significant trend towards the licensing out of innovative drugs from China, with the number of transactions increasing from 3% in 2019 to 13% in 2024 [23] - The report emphasizes the importance of AI and other technological advancements in driving growth within the medical device and pharmaceutical sectors [30][36]

Group 1 - The most challenging times for the pharmaceutical industry may have passed, as indicated by the optimism of fund managers regarding the recovery of the sector [1][3] - The Hong Kong innovative drug sector has shown significant strength, with the Hang Seng Healthcare Index rising by 31.89% since the beginning of the year, outperforming other major indices [2] - Over 251 out of 282 pharmaceutical-themed funds in the A-share market have achieved positive returns this year, with 66 funds seeing gains exceeding 20% [2] Group 2 - The rebound in the Hong Kong innovative drug sector is driven by policy support and improvements in the industry fundamentals, with a shift in market expectations from pessimism to a more neutral outlook [3][4] - The Chinese innovative drug industry is entering a new phase, with significant global competitiveness and an expected increase in the share of international collaborations by 2025 [3][4] - Fund managers are focusing on two main investment themes: the international expansion of innovative drugs and the integration of technology, while also considering structural opportunities in specific segments [6][7] Group 3 - The investment outlook for the pharmaceutical sector is optimistic, with expectations of dual increases in profitability and valuation due to ongoing policy optimization and market recovery [4][6] - The focus on innovative drugs, medical devices, and life sciences services is expected to yield faster performance recovery, particularly in the ADC and multi-antibody drug segments [6][7] - The potential for domestic replacement and accelerated international expansion in the innovative drug sector is highlighted, along with the positive impact of improved payment systems on growth opportunities [7]

Investment Rating - The industry investment rating is "Positive" and maintained [8] Core Insights - DKK1, a new potential target for solid tumors, is a typical secretory antagonist of the Wnt signaling pathway, showing high expression in various cancers, including gastric cancer and colorectal cancer [2][5] - Multiple pharmaceutical companies globally are proactively positioning themselves around the DKK1 target, with Junshi Bioscience's JS015, Anjiesheng's AGA2118, and Eli Lilly's Sirexatamab leading in clinical development, all having entered Phase II trials [6][23] - The macro environment has changed significantly, with a focus on two main investment directions for 2025: innovation going global and domestic demand recovery [7] Summary by Sections DKK1 Target Overview - DKK1 is a secretory glycoprotein that acts as an antagonist in the Wnt signaling pathway, with high expression in cancer patients' serum, particularly in gastric and colorectal cancers [5][18] - The potential of DKK1 as a biomarker for gastric cancer screening is highlighted, with its high expression correlating with poor prognosis [22] Clinical Development Progress - Junshi Bioscience's JS015 has shown promising early clinical data, with an overall response rate (ORR) of 100% in the first-line treatment of colorectal cancer and 66.7% in gastric cancer [6][26] - The clinical progress of DKK1-targeted therapies includes several companies, with Junshi's JS015, Anjiesheng's AGA2118, and Eli Lilly's Sirexatamab all in Phase II trials, while Pfizer's RN564 is in Phase I [25][23] Investment Opportunities - The report emphasizes the importance of innovative drugs and their potential for international expansion, suggesting that domestic policies favoring high-quality innovation will drive growth [7][30] - The recovery of domestic demand is expected to benefit sectors such as traditional Chinese medicine and consumer healthcare, with a focus on companies with strong cash flow and innovative capabilities [30][31]

近年来，中国生物医药产业发展进入了一个全新阶段：既保持着高速的研发和临床试验增量，也在由传统引进向自主创新输出的方向转变发展。 中国创新药企业正在不同治疗领域和技术路线上展现出显著的专业化和差异化布局，不少管线及上市产品实现"中国新"乃至"全球新"，全球生物医药版图迎 来更多中国声音。 随着中国生物医药逐渐由传统引进向自主创新输出的方向转变发展，创新药"出海"也出现新的变化。 医药魔方数据显示，2024年中国创新药对外授权交易（License-out）完成94笔，出海交易总金额高达519亿美元，同比增长26%；2025年1~3月，中国 License-out交易已有41起，总金额达369.29亿美元，均再创同期历史新高。 近日，由国际药物信息协会（下称"DIA"）主办的"2025国际药物信息大会"在上海举行，这个全球医药健康研发领域的盛会，吸引来自全球30余个国家和地 区、近百家国内外顶尖临床试验机构及200余家行业领先企业等参展交流。 近年来，中国生物医药产业发展进入了一个全新阶段：既保持着高速的研发和临床试验增量，也在由传统引进向自主创新输出的方向转变发展。综合前瞻产 业研究院、弗若斯特沙利文等机构数据， ...

Investment Rating - The report maintains a "Positive" investment rating for the healthcare sector [9]. Core Insights - DKK1, a new potential target for solid tumors, is a typical secretory antagonist of the Wnt signaling pathway, showing high expression in various cancers, including gastric and colorectal cancer [2][6]. - Multiple pharmaceutical companies globally are proactively positioning themselves around the DKK1 target, with leading candidates such as Junshi Bioscience's JS015, Anjiesheng's AGA2118, and Eli Lilly's Sirexatamab all in Phase II clinical trials [7][28]. - The report highlights the promising early clinical data for Junshi Bioscience's JS015, which shows a 100% overall response rate (ORR) in the first-line treatment of colorectal cancer (CRC) and significant efficacy in gastric cancer (GC) [31]. Summary by Sections DKK1 Target Overview - DKK1 is a secretory glycoprotein that acts as an antagonist in the Wnt signaling pathway, with high expression levels in the serum of cancer patients, particularly those with gastric cancer [22][27]. - The potential of DKK1 as a biomarker for gastric cancer screening is noted, with its high expression correlating with poor prognosis [27]. Clinical Development - Junshi Bioscience's JS015 has shown robust early clinical data, with a 100% ORR in a trial group for first-line CRC treatment and 66.7% ORR for first-line GC treatment [31]. - The report details the global clinical progress of DKK1-targeted therapies, with several candidates in various stages of clinical trials, indicating a competitive landscape [33]. Market Outlook - The report anticipates significant growth in the pharmaceutical sector by 2025, driven by innovation and recovery in domestic demand, particularly for innovative drugs and medical devices [8][35]. - The investment thesis emphasizes the importance of companies with strong cash flow, innovative capabilities, and established research platforms, particularly in the context of international market expansion [35][36].

本周（5月19日至23日，下同），三大指数全线调整。分行业来看，贵金属、汽车、包装等行业板块涨 幅居前，互联网、工业机械、酒类等行业板块跌幅靠前。市场上分化较为严重。 利好频发 在消息面上，本周LPR迎来年内首降，1年期降至3%，5年期以上降至3.5%，均下降10个基点。中国人 民银行行长潘功胜日前主持召开金融支持实体经济座谈会并讲话。会议重申，要实施好适度宽松的货币 政策，满足实体经济有效融资需求，保持金融总量合理增长。 近日，利好频发。 5月23日召开的国务院常务会议审议通过了《制造业绿色低碳发展行动方案（2025— 2027年）》。 会议指出， 推进制造业绿色低碳发展是大势所趋，要加快绿色科技创新和先进绿色技术推广应用，强 化新型工业化绿色底色。要推进传统产业深度绿色转型， 结合大规模设备更新等政策实施，积极应用 先进装备和工艺，加快重点行业绿色改造升级。要引领新兴产业高起点绿色发展，加大清洁能源、绿色 产品推广，提升资源循环利用水平。要加强共性技术攻关，完善重点领域标准， 优化相关政策，健全 绿色制造和服务体系，更好支持和帮助企业转型升级。 此前一日（5月22日），国新办举行新闻发布会，介绍科技金融政 ...

"医药行业最困难的时刻可能已经过去了。" 融通基金 基金经理万民远的一句感慨道出了众多医药基金经理、基民和股民多年持仓的坚守与转折。随着港 股创新药的牛市行情仍在持续演进，今年不少基民发现，自己持有亏损多年的医药基金开始赚钱了。 近期港股创新药板块持续走强，医药股、医药基金投资价值再次引起市场关注。证券时报·券商中国记者采访 国泰基金麻绎文、景顺长城基金金璜、融通基金万民远、金鹰基金欧阳娟、华富基金廖庆阳、诺安基金唐晨等 多位基金经理，围绕市场反弹动因、全年主线逻辑及细分赛道机会展开深度解读。 接受采访的多位基金经理均认为，港股创新药板块的上涨并非短期情绪驱动，而是政策红利、产业升级、全球 化突破等长周期逻辑的集中体现。尽管短期需关注政策落地节奏与外部环境变化，但中国创新药从"跟 跑"到"领跑"的趋势已然确立，在全球产业链中的价值重估进程方兴未艾。对于投资者而言，把握创新药出海 与技术融合主线，兼顾低估值修复与业绩兑现逻辑，或是分享产业升级红利的关键。 医药行业最困难时刻或已过去 Wind数据显示，年初低位以来，恒生医疗保健指数（HSHCI.HI）上涨达到31.89%，远超同期恒生科技指数和 恒生中国企业指数 ...

Core Viewpoint - Heng Rui Pharmaceutical officially listed on the Hong Kong Stock Exchange on May 23, 2023, marking a significant milestone in its internationalization strategy and achieving the largest financing scale in the Hong Kong pharmaceutical sector since 2020 [1][9]. Group 1: Listing Details - Heng Rui Pharmaceutical's IPO involved a global offering of approximately 225 million H-shares at an issue price of HKD 44.05, raising approximately HKD 9.89 billion [1]. - The stock opened at HKD 57 per share, a 29.4% increase from the issue price, and closed at HKD 55.15, a 25.2% increase [1]. - The listing is the second largest IPO in Hong Kong for 2025, following the leading battery manufacturer CATL [1]. Group 2: Company Leadership and Strategy - Vice Chairman Dai Hongbin emphasized that the listing is a crucial step for Heng Rui to enter the international capital market and accelerate its innovation and internationalization [2][3]. - The company aims to leverage this listing to enhance its global cooperation network and continue its focus on innovative research and development [3][10]. - Dai Hongbin's recent appointment as Vice Chairman reflects a strategic shift in the company's leadership, allowing him to play a more significant role in external communications and strategic planning [6]. Group 3: Historical Context and Future Outlook - Heng Rui Pharmaceutical, founded in 1970, has evolved from a local pharmaceutical factory to a significant player in the Chinese pharmaceutical industry, previously reaching a market value of over 600 billion yuan [7]. - The company has established 14 R&D centers globally and initiated over 20 overseas clinical trials, indicating its commitment to international expansion [10]. - The funds raised from the IPO will support clinical research and the development of innovative platforms, aiming to create first-in-class and best-in-class products [11].